Grinta, Inc.

Businessfiled

Grinta, Inc. operates in Pharma, based in DOVER. Cairo-based startup Grinta, a fintech-enabled B2B tech platform digitising the pharmaceutical supply chain, has raised US$8 million seed funding round to scale its full-stack tech platform, expand its team and accelerate growth across the Egyptian market.

Sub-sector tags: fintech, pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Grinta, Inc. has raised $9.5M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $8.0M on 2022-11-22.

Most recent recorded round closed around 2022-11-22.

Valuation (modeled)modeled

Provath models Grinta, Inc. at approximately $85M (range $9.2M–$266M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.24× the median modeled value of Series A Pharma companies in 2022–2024 (24 peers) — value vs value, same stage and era. Within the normal band (124% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 6 months.

Last raise 3.6 yr ago; this sector typically re-raises about every 16 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

The last round stepped up 1.4× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 65% of Pharma peers (310 compared).

Modeled value ranks above 64% of those peers.

Closest niche peers: Carmine Therapeutics, Inc., Triomics, Inc., Spiral Therapeutics Inc, Convelo Therapeutics, Inc., ADvantage Therapeutics, Inc..

Peoplefiled

1 named person on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.